A Phase Ib/II Study Evaluating The Safety And Efficacy Of Obinutuzumab In Combination With Polatuzumab Vedotin And Lenalidomide In Patients With Relapsed Or Refractory Follicular Or Diffuse Large B-Cell Lymphoma

Brief description of study

If you have been diagnosed with Relapsed Or Refractory Follicular Or Diffuse Large B-Cell Lymphoma, you may be qualified to participate in this phase Ib/II stduy. The main goal of this study is to test the safety of obinutuzumab or rituximab in combination with polatuzumab vedotin and lenalidomide at different dose levels and to find out what effects, good and/or bad, the study treatment has on you and your Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL).


Clinical Study Identifier: s15-01128
ClinicalTrials.gov Identifier: NCT02600897
Principal Investigator: Catherine M Diefenbach
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.